Pazufloxacin mesilate Chemical Properties

Melting point:

>255°C (dec.)

alpha 

D20 -64.2° (c = 1 in 1.0N NaOH)

storage temp. 

-20°C Freezer

solubility 

Aqueous Base (Slightly), DMSO (Slightly)

form 

Solid

color 

Off-White to Pale Yellow

CAS DataBase Reference

163680-77-1(CAS DataBase Reference)

Safety Information

Hazard Codes 

Xi,C,F

Risk Statements 

36/37/38-34-11

Safety Statements 

26-45-36/37/39-16

RTECS 

UU8815400

HS Code 

29349990

Pazufloxacin mesilate Usage And Synthesis

Description

This fluoroquinolone was co-developed by Toyama and Mitsubishi Pharm and was launched for the intravenous therapy of respiratory, urinary, surgical, gynecological and systemic infections.

Description

Pazufloxacin is a broad-spectrum synthetic fluoroquinolone antibiotic. It is active against Gram-negative and Gram-positive bacteria, including clinical isolates of E. coli, K. pneumoniae, methicillin-susceptible and -resistant S. aureus, and methicillin-susceptible and -resistant S. epidermidis (MIC₉₀s = 0.05, 0.1, 0.39, 12.5, 0.39, and 6.25 μg/ml, respectively). It inhibits E. coli, P. aeruginosa, and S. aureus DNA gyrase (IC₅₀s = 0.88, 1.9, and 10.2 μg/ml, respectively) and S. aureus topoisomerase IV (IC₅₀ = 24.2 μg/ml) in cell-free assays. In vivo, pazufloxacin is active against systemic E. coli, K. pneumoniae, and methicillin-resistant S. aureus infections in mice (ED₅₀s = 0.15, 5.5, and 4.5 mg/kg, respectively).

Chemical Properties

Crystalline Solid

Uses

A fluorinated quinolone antibiotic. Antibacterial.

Synthesis

Pazufloxacin Mesilate is elegantly synthesized from commercially available 2,3,4,5-tetrafluorobenzoic acid (168) by an 11-step process with an overall yield 48% [68]. Starting material 168 was first treated with ethyl bromide and then with t-butyl cyanoacetate in the presence of potassium carbonate in DMSO in one flask to give acylated cyanoacetate 169. Intermediate 169 thus obtained without purification was refluxed in toluene with p-TSA to yield 4- cyanomethylbenzoate 170 in 90% yield from 168. Cyclopropanation at the benzylic position of 170 was performed by |á,|á-dialkylation with two equiv. of 1,2- dibromoethane under phase-transfer conditions to give cyanocyclopropyl compound 171. Cyano compound 171 was subjected to hydration with alkaline H2O2 to afford carboxamide 172 in 81% yield from 170. Subsequently, carboxamide 172 was treated with NaOCl for Hofmann rearrangement to give primary amine 173, which was protected as its N-acetyl derivative 174 for the next reaction. Treatment of 174 with imidazole in the presence of thionyl chloride and TEA generated an imidazolide intermediate, which was converted to |?-keto ester 175 by reacting with potassium ethyl malonate and MgCl2. Enamine 176 was obtained without purification by successive treatment of 175 with DMF-dimethylacetal and (S)-(+)-2-aminopropanol. Crude 176 was heated in DMSO in the presence of potassium carbonate to efficiently give tricycle product 177 in 80% yield from 174. Finally, the ethyl ester and acetamide in 177 were hydrolyzed under basic and acidic conditions, respectively, to give the free amine. Pazufloxacin mesilate (20) was obtained in 94% yield by treatment of its corresponding free amine with methanesulfonic acid in ethanol.

Pazufloxacin mesilate(163680-77-1)Related Product Information

• 5-Amino-2-methylpyridine
• 4-Aminopyridine
• Pefloxacin mesylate
• 3-Aminopyridine
• METSULFURON METHYL
• Bensulfuron methyl
• Kresoxim-methyl
• Methyl salicylate
• Thiophanate-methyl
• Methanesulfonic acid
• Phentolamine mesilate
• 4-Dimethylaminopyridine
• Methyl
• Fluorine
• PAZUFLOXACIN (PREPARATION FOR PAZUFLOXACIN MESILATE)
• Methyl bromide
• PAZUFLOXACIN MESYLATE
• methanesulfonate